Brief: Biocryst Pharmaceuticals - Orladeyo Generally Well Tolerated, And Safety Consistent With Entire Apex-S Population
10/11/2023 12:09
Nov 10 (Reuters) - BioCryst Pharmaceuticals Inc
BCRX.O :
* BIOCRYST PRESENTS NEW REAL-WORLD DATA SHOWING REDUCED
ATTACK
RATES IN PATIENTS WITH HAE WITH NORMAL C1-INHIBITOR FOLLOWING
LONG-TERM TREATMENT WITH ORLADEYO® (BEROTRALSTAT)
* BIOCRYST PHARMACEUTICALS INC - ORLADEYO WAS GENERALLY WELL
TOLERATED, AND SAFETY WAS CONSISTENT WITH THAT OF ENTIRE APEX-S
POPULATION
* BIOCRYST PHARMACEUTICALS - PATIENTS WHO WERE TREATED WITH
ORLADEYO EXPERIENCED A SUSTAINED REDUCTION IN HAE ATTACKS
COMPARED TO THEIR SELF-REPORTED BASELINE ATTACK RATES
Source text for Eikon: ID:nGNX7m7834
Further company coverage: BCRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioCryst Pharmaceuticals
See all newsUS RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Pharvaris' genetic disorder drug meets main goal in late-stage trial (updated)
Brief: Biocryst Announces Approval Of Orladeyo® For Pediatric Hae Patients In Japan
BioCryst Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Biocryst Pharmaceuticals, - Cash, Cash Equivalents, Restricted Cash And Investments $354 Million At June 30, 2026